74B+ linked, tokenized data points built to answer critical clinical questions
Cohort SmartBuilder validates feasibility early to cut amendments and recruitment delays. By testing inclusion and exclusion criteria against real-world U.S. EMR and claims data, teams see risks sooner, locate patient concentrations, and provide transparent, data-backed justification for every protocol decision.
The tool combines curated U.S. patient data with Citeline’s gold-standard datasets to deliver fast feasibility insights. Adjust criteria with intuitive filters, see how recruitable populations change, and export summaries to align teams and support submissions.
Feasible cohorts are the foundation of trial success. Without them, recruitment falters, timelines slip, and costs rise. Cohort SmartBuilder reduces risk, improves decisions, and grounds every protocol in real-world patient availability.
Instantly see how inclusion and exclusion criteria affect recruitable patient populations.
Visualize where eligible patients are concentrated across U.S. geographies.
Change criteria with simple filters and watch feasibility numbers update in real time.
Export cohort summaries to align cross-functional teams and support submissions.
Access curated, protocol-ready U.S. patient data without costly data licensing or prep work.
Download our strategic playbook to discover a smarter, unified approach to clinical planning and patient recruitment.
ある世界的な製薬会社は、乳がんの新しい治療法の臨床試験を実施する準備をしています。同社は、データ主導で効率的なアプローチを確実にするために、Citelineのソリューションスイートを使⽤して、試験計画と研究の開始を迅速化しています。これらのソリューションは、製薬会社がプロトコルの開発、治験責任医師および施設の選択に⻑年頼ってきたTrialtroveとSitetroveの臨床試験データのゴールドスタンダードに基づいて、主要な試験パラメータに関する即時の推奨事項を提供します。
